Obesity
Conditions
Keywords
obesity, periodontal status, dietary inflammatory index
Brief summary
In this study aimed to investigate the effect of nutrition on periodontal status in individuals diagnosed with obesity and without any other systemic disease, and to investigate the relationship between DII and periodontal disease risk. A total of 200 participants will be included in the study. Participants' overall daily Dietary Inflammatory Index (DII) scores will be calculated. The obtained scores will be divided into four groups, from low to high: Q1 (n=50), Q2 (n=50), Q3 (n=50), and Q4 (n=50). According to the DII, groups Q1 and Q2, which include lower scores, represent individuals on an anti-inflammatory diet, while groups Q3 and Q4, which include higher scores, represent individuals on a pro-inflammatory diet. Interleukin (IL)-1β, IL-10, total oxidant status (TOS), and total antioxidant status (TAS) were collected from gingival crevicular fluid (GCF) and serum samples. The levels of biomarkers such as malondialdehyde (MDA), glutathione (GSH), leptin, adiponectin, tumor necrosis factor (TNF)-α and C-reactive protein (CRP) from serum samples alone will be analyzed by ELISA method at the Recep Tayyip Erdoğan University Medical Biochemistry Laboratory.
Interventions
OTHERPeriodontal indices will be obtained
Periodontal indices will be obtained from all participants
OTHERserum and crevicular fluid samples will be collected
Serum and gingival crevicular fluid samples will be collected from all participants.
Sponsors
Recep Tayyip Erdogan University Training and Research Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Inclusion criteria
* Being diagnosed with obesity, * Not having any systemic conditions other than obesity (systemic diseases that may affect periodontal health, such as cardiovascular disease, chronic kidney disease, Type 1 diabetes, Type 2 diabetes, and hypertension (\>130/85 mmHg)), * Being between the ages of 18 and 65, * Not smoking or consuming alcohol, * Not having used anti-inflammatory medications in the last 3 months, or antibiotics or systemic corticosteroids in the last 6 months, * Not being pregnant or lactating, * Not having received periodontal treatment in the last 6 months, * Not having received nutritional advice in the last 3 months, * Obesity diagnosis: BMI \> 30 kg/m2 or waist circumference: \> 100 cm for men and \> 90 cm for women.
Exclusion criteria
* Non-obese * Having any systemic disease other than obesity (such as cardiovascular disease, chronic kidney disease, Type 1 diabetes, Type 2 diabetes, and hypertension (\>130/85 mmHg) that may affect periodontal health) * Being over 65 years old and under 18 years old * Smoking and alcohol use * Having used anti-inflammatory drugs in the last 3 months, antibiotics, or systemic corticosteroids in the last 6 months * Being pregnant or lactating * Having received periodontal treatment in the last 6 months * Having received nutritional advice in the last 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Periodontal pocket depth | baseline | The distance between the pocket base and the gingival margin will be measured. It will be measured from the six surfaces of each tooth and the average will be taken higher scores indicate worse outcome. |
| Clinical attachment loss | baseline | It will be calculated by measuring the distance between the cementoenemal border and the pocket base. It will be measured from the six surfaces of each tooth and the average will be taken higher scores indicate worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| interleukin (IL)-1β level | baseline | IL-1β levels will be measured with biochemical kits. |
| interleukin (IL)-10 level | baseline | IL-10 levels will be measured with biochemical kits. |
| total oxidant status (TOS) level | baseline | TOS levels will be measured with biochemical kits. |
| total antioxidant status (TAS) level | baseline | TAS levels will be measured with biochemical kits. |
| serum leptin level | baseline | Leptin levels in serum will be measured with biochemical kits. |
| serum tumor necrosis factor (TNF)-α level | baseline | TNF-α levels in serum will be measured with biochemical kits. |
| serum adiponectin level | baseline | Adiponectin levels in serum will be measured with biochemical kits. |
| serum C-reactive protein (CRP) level | baseline | CRP levels in serum will be measured with biochemical kits. |
| serum malondialdehyde (MDA) level | baseline | MDA levels in serum will be measured with biochemical kits. |
| serum glutathione (GSH) level | baseline | GSH levels in serum will be measured with biochemical kits. |
Countries
Turkey (Türkiye)
Outcome results
None listed